Last reviewed · How we verify

NCT00144261

An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects

Completed Phase 4 Last updated 31 January 2025
What this trial tests

Phase 4 trial testing nevirapine in HIV Infections in 15 participants. Completed.

Timeline
1 November 2003
Primary endpoint
1 December 2006

Quick facts

Lead sponsorBoehringer Ingelheim
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Primary purposeprevention
Enrollment15
Start date1 November 2003
Primary completion1 December 2006
Sites3 locations across United Kingdom, Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

18 and older, any sex, with HIV Infections or Metabolism, Lipids. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP containing treatment were evaluated. In addition, the activity of the key enzymes related to HDL metabolism were assessed. \[ Designated as safety issue: No \] 2. In order to determine the relevance of the HDL increase in decreasing cardiovascular risk in HIV-positive subjects we evaluated endothelial function (FMD) as a surrogate marker for cardiovascular disease in patients. \[ Designated as safety issue: No \]

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of nevirapine

Trials testing the same drug.

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

Other Boehringer Ingelheim trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00144261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing